Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced top-line results of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for glaucoma.